Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.

Press Releases

Dr. Christine Dingivan Joins Emmes as President and CEO
Emmes today announced that Dr. Christine Dingivan has joined the company as its new president and chief executive officer. She is succeeding Dr. Anne Lindblad, who is retiring after 38 years at the company. Dr. Dingivan will be Emmes’ fourth chief executive since the company was founded in 1977.
Emmes Announces its Role in Phase 1 COVID-19 Vaccine Trial
Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, “An mRNA Vaccine against SARS-CoV-2,” published in the New England Journal of Medicine on July 14.
Emmes Promotes Three VPs to Officer Positions
Emmes today announced that three corporate vice presidents have been promoted. Dr. Traci Clemons has been named chief research officer, Marian Ewell is now chief scientific innovation officer, and Jennifer Hester is the company’s chief human resources officer. These are all newly created positions for the company. According to Dr. Anne Lindblad, president and chief executive officer, “Elevating these roles – research, scientific innovation, and human resources – is a tremendous step forward in our company’s evolution. It’s an endorsement for how far we’ve come as a major player supporting clinical trials and research for a wide range of human health issues. It reflects our growth and diversification across both government and commercial sectors. And finally, it’s a testament to the value of these three outstanding professionals, and the role they’ve played and will continue to play in our success.”
Emmes Chosen as a Top Area Workplace
Emmes today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2020 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post partnered with employee research and consulting firm Energage, LLC, to conduct the survey, and the highest ranked workplaces were chosen based on employee responses about their own company. There were 3,500 area companies invited to participate, and 406 were surveyed. This is the seventh year the survey has been conducted.
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
Emmes today announced that it provided the Phase 3 clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant. Emmes’ work for Gamida Cell Ltd. , an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, involved full scope clinical trial support for this study that was conducted at more than 50 centers in the United States, Latin America, Europe and Asia. Emmes also supported the early development Phase 1 and 2 trials that began in 2010.
Emmes Announces its Contribution to NIH ACTT Clinical Trial for Remdesivir
Emmes today announced that its data and statistical analysis work for the Adaptive COVID-19 Treatment Trial (ACTT) played an important role in the accelerated timetable to evaluate remdesivir’s effectiveness in treating hospitalized COVID-19 patients.
Emmes Ranked as a Top Biosciences Employer in Greater Washington
Emmes today announced that it was ranked as the seventh largest biosciences employer in the greater Washington area. The ranking is compiled annually by the Washington Business Journal. Emmes reported revenues of $125 million in 2019 and has more than 750 employees globally. More than 675 employees work in Maryland, Virginia and Washington, D.C.
Emmes today announced that Dr. Joe Sliman has been named the company’s chief medical officer (CMO)
According to Dr. Anne Lindblad, president and chief operating officer, “The depth and breadth of Joe’s biopharmaceutical and government experience will be extremely valuable in supporting both our government and commercial clients.”
Three Long-Time Emmes Employees Are Named VPs
Emmes today announced that Heather Hill, Dr. Adam Mendizabal and Dr. Nilay Shah have been promoted to vice president. According to Dr. Anne Lindblad, president and chief executive officer, “These promotions reflect their talent and value to the organization. Heather, Adam and Nilay demonstrate our commitment to developing staff and promoting from within. They will strengthen and add great value to our leadership team and will support our plans to grow both internally and externally.”
Kathleen Wolf Joins Emmes as VP of Clinical Operations
Emmes today announced that Kathleen Wolf has joined the company as vice president of clinical operations. She has two decades of leadership experience in the biopharmaceutical industry, including most recently as a senior director with AstraZeneca’s MedImmune unit. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “Kathleen is an outstanding addition to our leadership team. Her background in both biotech and pharmaceutical settings will be a great asset. Her experience in building collaborative, cross-functional teams complements our clinical operations platform.”
Emmes Study Leads to Pediatric Drug Labeling Change for Ampicillin
Emmes today announced that the Food and Drug Administration (FDA) has extended the labeling of ampicillin, a commonly used antibiotic, to include use in infants younger than 28 days in the treatment of serious conditions meningitis and septicemia. FDA’s approval was based in part on a National Institute of Child Health and Human Development (NICHD)-funded study, conducted under the Best Pharmaceuticals for Children Act (BPCA).
Emmes Studies Contribute to FDA Approval of a Medical Device That Estimates the Weight of Infants
Emmes today announced that the U.S. Food and Drug Administration (FDA) has approved a prescription-only medical device used to estimate the weight of infants who are up to 90 days of age.